Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06545942 · ClinicalTrials.gov registry record · Phase 1
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
A Phase 1 study of Breast Cancer and Prostate Cancer, sponsored by MOMA Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 220
- Enrollment target
- 18
- Study locations
NCT06545942: Recruiting Phase 1 study of Breast Cancer and Prostate Cancer, sponsored by MOMA Therapeutics.
NCT06545942 is a Phase 1 study of Breast Cancer and Prostate Cancer that is actively recruiting participants, run by MOMA Therapeutics. The registered enrollment target is 220 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (92% lower). The trial reports 18 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06545942, a Phase 1 study of Breast Cancer and Prostate Cancer, is actively recruiting participants, sponsored by MOMA Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 220 participants
- Enrollment target
- 18
- Study locations
Study Summary
This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clinical activity of MOMA-313 administered orally as a single agent or combination therapy in patients with homologous recombinant deficient solid tumors.
Primary Outcome
To assess the safety and tolerability of MOMA-313 given as a single-agent or in combination with olaparib
Conditions Studied
Interventions
- DRUG Olaparib
- DRUG MOMA-313
Study Locations (18)
Other
- Investigative Site #114 - Barcelona
- Investigative Site #116 - Barcelona
- Investigative Site #115 - Madrid
- Investigative Site #113 - London
- Investigative Site #117 - Manchester
- Investigative Site #118 - Newcastle upon Tyne
California
- Investigative Site #101 - La Jolla
- Investigative Site #111 - San Francisco
New York
- Investigative Site #103 - New York
- Investigative Site #106 - New York
Arizona
- Investigative Site #108 - Goodyear
Florida
- Investigative Site #104 - Lake Mary
Missouri
- Investigative Site #110 - St Louis
Pennsylvania
- Investigative Site #109 - Philadelphia
South Carolina
- Investigative Site #107 - Myrtle Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2024-08-13 |
| Est. Completion | 2027-11-30 |
| Phase | Phase 1 |
What NCT06545942 shows while recruiting
NCT06545942 is an interventional study that assigns participants to a tested intervention. The registered 220 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (92% lower).
The record links to 7 conditions, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Olaparib is the first listed.
NCT06545942 lists 18 locations in 11 states (Other, California, New York).
Frequently Asked Questions
What is clinical trial NCT06545942 about?
NCT06545942 is a clinical study titled "Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors". This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clinical activity of MOMA-313 administered orally as a single agent or combination therapy in patients wi...
What is the current status of trial NCT06545942?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 220 participants. The study started on 2024-08-13. Estimated completion is 2027-11-30.
What conditions does trial NCT06545942 study?
This clinical trial studies the following conditions: Breast Cancer, Prostate Cancer, Ovarian Cancer, Advanced Solid Tumor, Pancreas Cancer.
What interventions are being tested in trial NCT06545942?
The interventions under investigation include: Olaparib (DRUG), MOMA-313 (DRUG).
Who is sponsoring clinical trial NCT06545942?
This trial is sponsored by MOMA Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06545942 being conducted?
This trial has 18 study locations across Arizona, California, Florida, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06545942's enrollment target sits among peer trials
220 342nd of 1224 higher than 881 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00920972 · 220 participants · Phase 1
Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases
- NCT01851642 · 220 participants
Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs
- NCT02582021 · 220 participants
WISE CVD - Continuation (WISE HFpEF)
- NCT04067830 · 220 participants · Phase 2
Respiratory Muscle Training Before Surgery in Preventing Lung Complications in Patients With Stage I-IIIB Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI